Respiratory Drug Delivery 2019

SMi Group5 - 6 December 2019, London, UK.
SMi are pleased to announce the launch of the Respiratory Drug Delivery conference as part of the newly branded Asthma and COPD series. With the rising prevalence of respiratory disease such as Asthma, cystic fibrosis and COPD, this group of diseases are now amongst the leading cause of death, affecting over 500 million adults and children worldwide. Lung cancer now accounts for over 50% of all respiratory disease related deaths in Europe, yet little work is being done to reduce this high mortality rate.

Opportunities for drug development has effectively resulted in the global pulmonary and respiratory drug delivery market expecting to reach 64 billion USD (6.7% CAGR) by 2025. However, the unmet medical needs of respiratory diseases sufferers remain.

Join SMi this year as they aim to bring together clinical researchers, respiratory drug manufacturers and solution providers to discuss the current research and developments in providing appropriate long-term treatments that adhere to patient's needs, analysing the success of digital media devices and connective health technology in aiding the diagnosis of severe asthma and COPD. This year will also investigate the developing issues surrounding pulmonary and nasal combination product design.

Benefits of attending:

  • Assessing how to transform disease management through drug combinations, devices and inhaled biological treatments
  • Evaluating respiratory device design development and novel technologies such as nanoparticle-based drug delivery
  • Exploring digital connective inhalation to improve patient centricity
  • Reviewing the challenges around the pricing and reimbursement of respiratory drug products

View the full agenda online: www.respiratorydrugdelivery.com/wpnwl

Early bird rates:

  • Book by 30th September and save £100

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

A step closer to cancer precision medicine

Researchers from the Faculty of Medicine and the Institute for Molecular Medicine (FIMM) at the University of Helsinki have developed a computational model, Combined Esse...

Artificial Intelligence algorithm can learn the la…

Artificial Intelligence can be used to predict molecular wave functions and the electronic properties of molecules. This innovative AI method developed by a team of resea...

Amgen completes acquisition of Otezla® (apremilast…

Amgen (NASDAQ:AMGN) today announced the successful completion of its acquisition of worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for mo...

Bristol-Myers Squibb completes acquisition of Celg…

Bristol-Myers Squibb Company (NYSE:BMY) has completed its acquisition of Celgene Corporation (NASDAQ:CELG) following the receipt of regulatory approval from all governmen...

Amgen and the Duke Clinical Research Institute ann…

Amgen (NASDAQ:AMGN) in collaboration with the Duke Clinical Research Institute (DCRI) announced plans to initiate the Cardiovascular Multi-dimensional Observational Inves...

Statins not associated with memory or cognition de…

Given consumer concern that statins may be associated with memory or cognitive decline, a new study published today in the Journal of the American College of Cardiology m...

Novartis announces new strategy to provide innovat…

Novartis announced a new strategy to broaden patient reach and availability of its portfolio of medicines in sub-Saharan Africa (SSA), which is home to the largest unders...

New advances in the treatment of advanced lung can…

The University of Barcelona (UB) and Hospital Clínic de Barcelona collaborate with Boehringer Ingelheim Inc. to improve the efficiency of nintedanib, an antiangiogenic an...

FDA grants priority review to Roche’s risdiplam fo…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Review for ...

A protein tag to study the immune system

Researchers from VIB-UGent Center for Medical Biotechnology, University of Iowa (USA) and other collaborators, developed a novel approach to better understand a basic def...

Bayer and Dewpoint Therapeutics partner to researc…

Bayer and Dewpoint Therapeutics, a biotechnology company with sites in Boston and Dresden, Germany, today announced an option, research and license agreement worth up to ...

Pharmacist-led interventions may help prevent card…

With their expertise in the safe and effective use of medications, pharmacists can help in the management of chronic diseases. A review and analysis published in the Brit...